← All companies
Psychedelic drug developers
Entropy Neurodynamics
ASX: ENP · formerly Tryp Therapeutics, Tryptamine Therapeutics, Exopharm · Australia
Listed outside the U.S. See the ASX: ENP quote ↗
Why we cover it
An Australian-listed company that took over Tryp Therapeutics in a 2024 reverse merger and has been renamed twice since: Exopharm, then Tryptamine Therapeutics, then Entropy Neurodynamics.
Financials
Recent financials aren't available in a standard format for this company. See its listing ↗
Clinical trials Trials tracker
| Trial | Compound | Stage |
|---|---|---|
| TRP-8803 for Binge Eating Disorder and Beyond | Psilocybin | Phase 2 (expanding to 8-indication basket trial) |
In the Journal (4)
- Sep 29, 2026 Only 3 of 10 Psychedelic Companies Lobby Washington. One Just Joined — Twice, in the Same Quarter.
- Sep 23, 2026 Which Psychedelic-Company CEO's Pay Actually Matched Their Stock's Performance? We Checked All 10 — Almost None Did.
- Sep 17, 2026 The Psychedelic Money Graveyard: Renames, Reverse Mergers, and the Companies That Didn't Make It
- Sep 11, 2026 The Psychedelic Money Rankings: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments
Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.